InsidersTradesSigma
Follow the ORTHOPEDIATRICS CORP stock price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, ORTHOPEDIATRICS CORP has recorded 150 public disclosures. Market capitalisation: €639.7m. The latest transaction was reported on 26 August 2026 (Cession). Among the most active insiders: Odle Gregory A. The full history is accessible without an account.
150
Insider Decl.
n/a
Thresholds
€325,404
6 ops.
Buy Volume
€9m
53 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate ORTHOPEDIATRICS CORP Buy (bullish), based on 9 analysts. Average price target: US$27.22.
33Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 22,929 of 28,958 companies
31.2
score / 100
Value24
Quality38
FCF yld-2.6%
Earn yld-6.4%
EV/EBITDA·
ROE-11%
Gross mgn73%
Net mgn-17%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 26 August 2026
Declarations150 total
4,000 shares@ US$25.75Common StockSEC:0001193125-26-369063:0
16,300 shares@ US$24.74Common StockSEC:0001193125-26-369063:1
18,000 shares@ US$24.28Common StockSEC:0001193125-26-369063:2
4,000 shares@ US$25.75Common StockSEC:0001193125-26-369065:0
16,300 shares@ US$24.74Common StockSEC:0001193125-26-369065:1
18,000 shares@ US$24.28Common StockSEC:0001193125-26-369065:2
4,000 shares@ US$25.75Common StockSEC:0001425450-26-000081:0
16,300 shares@ US$24.74Common StockSEC:0001425450-26-000081:1
18,000 shares@ US$24.28Common StockSEC:0001425450-26-000081:2
119,140 sharesCommon StockSEC:0001425450-26-000056:0
11,436 sharesCommon StockSEC:0001425450-26-000052:0
11,436 sharesCommon StockSEC:0001425450-26-000059:0
2,479 shares0Common StockSEC:0001425450-26-000038:0
65,700 shares0Common StockSEC:0001425450-26-000023:0
47,380 shares0Common StockSEC:0001425450-26-000020:0
47,380 shares0Common StockSEC:0001425450-26-000019:0
19,535 shares@ US$17.2538.9% of flowCommon StockSEC:0001425450-26-000021:0
1,600 shares0Common StockSEC:0001425450-25-000124:0
4,345 shares0Common StockSEC:0001425450-25-000122:0
8,401 shares0Common StockSEC:0001425450-25-000067:0
8,401 shares0Common StockSEC:0001425450-25-000077:0
8,401 shares0Common StockSEC:0001425450-25-000075:0
8,401 shares0Common StockSEC:0001425450-25-000069:0
25 of 150 declarations
About ORTHOPEDIATRICS CORP
OrthoPediatrics Corp. (ticker: KIDS) is a U.S.-based medical device company listed on the Nasdaq, and its strategic identity is unusually focused: it is devoted exclusively to pediatric orthopedics. Headquartered in Warsaw, Indiana, United States, the company was founded in 2006 with the goal of addressing an underserved niche within orthopedics—devices and systems designed specifically for children and adolescents rather than scaled-down adult products. That focus is a key competitive advantage versus larger, more diversified medtech peers. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1425450/000142545026000013/0001425450-26-000013-index.htm?utm_source=openai)) The company markets nearly 90 surgical and bracing systems spanning three of the largest pediatric orthopedic categories: trauma and deformity, scoliosis, and sports medicine/other procedures. Its portfolio includes implants, instruments, and procedure-specific systems used by pediatric orthopedic surgeons, alongside an expanding specialty bracing business. Recent acquisitions such as Boston Orthotics & Prosthetics and MD Orthopaedics have broadened the non-operative side of the platform and deepened the company’s ability to serve patients across the treatment continuum, including clubfoot and other bracing indications. ([ir.orthopediatrics.com](https://ir.orthopediatrics.com/news-releases/news-release-details/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2025?utm_source=openai)) From a market-positioning standpoint, OrthoPediatrics benefits from its exclusive pediatric specialty model. Rather than competing broadly across adult orthopedics, it concentrates resources on surgeon education, product innovation, and relationships with pediatric hospitals and specialists. Management also emphasizes a global commercial footprint: products are sold in the United States and in more than 75 countries outside the U.S., giving the company geographic diversification while keeping its core operating base in the domestic market. ([ir.orthopediatrics.com](https://ir.orthopediatrics.com/news-releases/news-release-details/orthopediatrics-corp-reports-fourth-quarter-and-full-year-2025?utm_source=openai)) Recent business developments have been constructive. In 2025, the company expanded its Specialty Bracing Division into new territories and opened additional clinics, underscoring a push to build a more integrated pediatric care platform. It also announced a distribution partnership with MY01 to widen access to technology aimed at pediatric trauma patients. Financially, OrthoPediatrics reported strong momentum into 2026, including 13% year-over-year revenue growth in the first quarter of 2026 to $59.4 million and 15% full-year 2025 revenue growth to $236.3 million, while also highlighting improved cash generation. These updates point to a business that is still investing, but increasingly demonstrating operating leverage and commercial scale. ([ir.orthopediatrics.com](https://ir.orthopediatrics.com/news-releases/news-release-details/orthopediatrics-corp-announces-continued-expansion-specialty?utm_source=openai))
